# Opaleye Management Inc. 13F holdings Q2 2026: $1.1 billion

Opaleye Management Inc. reported $1.1 billion in 13F securities across 58 positions for the quarter ended June 30, 2026, in a holdings report filed August 14, 2026. Its largest holding was Liquidia Corporation at $195 million, 17.7% of the reported value. Since Q1 2026 it opened 13 new positions and exited 9.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $1,104,182,260
- Positions: 58
- Filed: August 14, 2026
- Report type: 13F holdings report
- CIK: 1595855
- Form 13F file number: 028-15896
- CRD number: 124513
- Business address: One Boston Place Suite 2600, Boston, MA 02108
- SEC filing: [0001420506-26-001803](https://www.sec.gov/Archives/edgar/data/1595855/000142050626001803/0001420506-26-001803-index.htm)
- Investment adviser record: [Form ADV on SpecStream](https://specstream.ai/data/investment-advisers/firm/opaleye-management-inc-124513)

## Top 25 holdings by value

The largest of 58 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [Liquidia Corporation](https://specstream.ai/data/institutional-holders/liquidia-corporation-53635d202) | COM NEW | 2,447,500 | $195.1 million | -97,500 |
| [Eton Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/eton-pharmaceuticals-inc-29772l108) | COM | 2,860,000 | $103.5 million | No change |
| [Harrow Inc](https://specstream.ai/data/institutional-holders/harrow-inc-415858109) | COM | 2,400,000 | $101.9 million | -432,230 |
| [Disc Medicine Inc](https://specstream.ai/data/institutional-holders/disc-medicine-inc-254604101) | COM | 855,000 | $62.5 million | +434,000 |
| [Urogen Pharma LTD](https://specstream.ai/data/institutional-holders/urogen-pharma-ltd-m96088105) | COM | 1,439,996 | $53 million | +9,996 |
| [Apogee Therapeutics Inc](https://specstream.ai/data/institutional-holders/apogee-therapeutics-inc-03770n101) | COM | 390,000 | $51.8 million | No change |
| [Meiragtx Hldgs PLC](https://specstream.ai/data/institutional-holders/meiragtx-hldgs-plc-g59665102) | COM | 3,550,000 | $48 million | +1,426,741 |
| [Sol-Gel Technologies LTD](https://specstream.ai/data/institutional-holders/sol-gel-technologies-ltd-m8694l137) | SHS NEW | 500,000 | $37.1 million | No change |
| [Rezolute Inc](https://specstream.ai/data/institutional-holders/rezolute-inc-76200l309) | COM NEW | 6,300,000 | $32.8 million | No change |
| [TG Therapeutics Inc](https://specstream.ai/data/institutional-holders/tg-therapeutics-inc-88322q108) | COM | 535,000 | $29.4 million | No change |
| [Immix Biopharma Inc](https://specstream.ai/data/institutional-holders/immix-biopharma-inc-45258h106) | COM | 2,345,000 | $24.2 million | New |
| [Crescent Biopharma Inc.](https://specstream.ai/data/institutional-holders/crescent-biopharma-inc-g2545c104) | COM | 1,319,351 | $23.7 million | +6,736 |
| [Stoke Therapeutics Inc](https://specstream.ai/data/institutional-holders/stoke-therapeutics-inc-86150r107) | COM | 700,000 | $22.9 million | No change |
| [Alpha Cognition Inc](https://specstream.ai/data/institutional-holders/alpha-cognition-inc-02074j501) | COM NEW | 2,895,467 | $20.9 million | +333,517 |
| [Edgewise Therapeutics Inc](https://specstream.ai/data/institutional-holders/edgewise-therapeutics-inc-28036f105) | COM | 500,000 | $20.3 million | No change |
| [Revolution Medicines Inc](https://specstream.ai/data/institutional-holders/revolution-medicines-inc-76155x100) | COM | 100,000 | $18.7 million | No change |
| [Monte Rosa Therapeutics Inc](https://specstream.ai/data/institutional-holders/monte-rosa-therapeutics-inc-61225m102) | COM | 745,000 | $18 million | New |
| [Alumis Inc](https://specstream.ai/data/institutional-holders/alumis-inc-022307102) | COM | 550,000 | $15.5 million | No change |
| [Codexis Inc](https://specstream.ai/data/institutional-holders/codexis-inc-192005106) | COM | 6,785,000 | $15.3 million | No change |
| [Replimune Group Inc](https://specstream.ai/data/institutional-holders/replimune-group-inc-76029n106) | COM | 1,384,993 | $15.3 million | New |
| [Xoma Royalty Corporation](https://specstream.ai/data/institutional-holders/xoma-royalty-corporation-98419j206) | COM NEW | 338,374 | $14.4 million | +38,374 |
| [MBX Biosciences Inc](https://specstream.ai/data/institutional-holders/mbx-biosciences-inc-55287l101) | COM | 260,000 | $14.4 million | No change |
| [Rhythm Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/rhythm-pharmaceuticals-inc-76243j105) | COM | 122,500 | $13.6 million | -500 |
| [Editas Medicine Inc](https://specstream.ai/data/institutional-holders/editas-medicine-inc-28106w103) | COM | 3,861,930 | $12.5 million | +1,934,933 |
| [Protagonist Therapeutics Inc](https://specstream.ai/data/institutional-holders/protagonist-therapeutics-inc-74366e102) | COM | 100,000 | $12.3 million | No change |

## New positions in Q2 2026

13 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Immix Biopharma Inc](https://specstream.ai/data/institutional-holders/immix-biopharma-inc-45258h106) | COM | 2,345,000 | $24.2 million |
| [Monte Rosa Therapeutics Inc](https://specstream.ai/data/institutional-holders/monte-rosa-therapeutics-inc-61225m102) | COM | 745,000 | $18 million |
| [Replimune Group Inc](https://specstream.ai/data/institutional-holders/replimune-group-inc-76029n106) | COM | 1,384,993 | $15.3 million |
| [Verastem Inc](https://specstream.ai/data/institutional-holders/verastem-inc-92337c203) | COM NEW | 1,800,000 | $6.9 million |
| [Phathom Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/phathom-pharmaceuticals-inc-71722w107) | COM | 185,589 | $2 million |
| [Inhibrx Biosciences Inc](https://specstream.ai/data/institutional-holders/inhibrx-biosciences-inc-45720n103) | COM | 20,291 | $1.9 million |
| [Hemab Therapeutics Hldgs Inc](https://specstream.ai/data/institutional-holders/hemab-therapeutics-hldgs-inc-423494103) | COM SHS | 47,652 | $1.8 million |
| [First Tracks Biotherapeutics](https://specstream.ai/data/institutional-holders/first-tracks-biotherapeutics-337185102) | ORD SHS | 65,000 | $1.3 million |
| [Biohaven LTD](https://specstream.ai/data/institutional-holders/biohaven-ltd-g1110e107) | COM | 77,915 | $1.2 million |
| [Pasithea Therapeutics Corp](https://specstream.ai/data/institutional-holders/pasithea-therapeutics-corp-70261f202) | COM NEW | 2,050,000 | $1.1 million |
| [Adc Therapeutics SA](https://specstream.ai/data/institutional-holders/adc-therapeutics-sa-h0036k147) | SHS | 700,000 | $749,000 |
| Okyo Pharma LTD | SHS NEW | 375,204 | $562,806 |
| [Palatin Technologies Inc](https://specstream.ai/data/institutional-holders/palatin-technologies-inc-696077601) | COM NEW | 20,500 | $221,195 |

## Positions exited in Q2 2026

9 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Perspective Therapeutics Inc](https://specstream.ai/data/institutional-holders/perspective-therapeutics-inc-46489v302) | COM NEW | 4,675,000 | $19.5 million |
| Assertio Holdings Inc | COM NEW | 265,707 | $5.1 million |
| [Sutro Biopharma Inc](https://specstream.ai/data/institutional-holders/sutro-biopharma-inc-869367201) | COM SHS | 190,671 | $4.7 million |
| [Tectonic Therapeutic Inc](https://specstream.ai/data/institutional-holders/tectonic-therapeutic-inc-878972108) | COM | 123,000 | $3.8 million |
| [Rigel Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/rigel-pharmaceuticals-inc-766559702) | COM | 70,000 | $1.9 million |
| [Nextcure Inc](https://specstream.ai/data/institutional-holders/nextcure-inc-65343e207) | COM NEW | 141,181 | $1.5 million |
| Perspective Therapeutics Inc | CALL | 200,000 | $834,000 |
| [Protalix Biotherapeutics Inc](https://specstream.ai/data/institutional-holders/protalix-biotherapeutics-inc-74365a309) | COM | 340,000 | $737,800 |
| [LB Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/lb-pharmaceuticals-inc-50180m108) | COM SHS | 14,506 | $357,718 |

## Also on SpecStream

- [Opaleye Management Inc. Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/1595855/000142050626001803/0001420506-26-001803-index.htm)
- [Opaleye Management Inc. investment adviser record (Form ADV)](https://specstream.ai/data/investment-advisers/firm/opaleye-management-inc-124513)
- [Largest 13F filers in Massachusetts](https://specstream.ai/data/institutional-holdings/state/massachusetts)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Boston, Massachusetts

- [Divorce and family law firms in Boston, Massachusetts](https://specstream.ai/data/businesses/divorce-and-family-law-firms/boston-massachusetts-united-states)
- [Bakeries in Boston, Massachusetts](https://specstream.ai/data/businesses/bakeries/boston-massachusetts-united-states)
- [Publishers in Boston, Massachusetts](https://specstream.ai/data/businesses/publishers/boston-massachusetts-united-states)
- [Locksmiths in Boston, Massachusetts](https://specstream.ai/data/businesses/locksmiths/boston-massachusetts-united-states)
- [Executive search firms in Boston, Massachusetts](https://specstream.ai/data/businesses/executive-search-firms/boston-massachusetts-united-states)
- [Business consulting firms in Boston, Massachusetts](https://specstream.ai/data/businesses/business-consulting-firms/boston-massachusetts-united-states)
